More than 3 million eye drops are being recalled over fears they could be contaminated and harm vision.

More than 3 million eyedrops have been recalled in the US because of a ‘lack of assurance of sterility’

Manufacturer K.C. Pharmaceuticals, based in California, issued the alert for its over-the-counter generic eye drop products due to a ‘lack of assurance of sterility’.

It is not clear whether any are contaminated, but the FDA has said this is a Class II recall, meaning there is a temporary, and reversible, risk to the eyes and vision if the products are used.

The eye drops were sold nationwide in 0.5 fl oz bottles and were on shelves at CVS, Walgreens, Kroger, H-E-B and other stores. Continue reading →

The root cause of our current health care affordability crisis is a broken market structure on the supply side resulting in out-of-control costs. The (apparently) core public policy issues: insurance, pre-existing conditions, employment linkage, lack of portability, the extent of coverage, denials, out of pocket costs, and deductibles would all become non-issues if health care was a normal expense that people could afford out of their income. Continue reading →

More than 140,000 bottles of America’s most prescribed drug are being recalled over fears the medication may not work properly.

The recall affects bottles of 10mg, 20mg, 40mg and 80mg tablets that were sold nationwide in 90-, 500- and 1,000-count bottles available by prescription

Ascend Laboratories, based in New Jersey, has pulled its statin atorvastatin calcium, a generic version of Lipitor, from shelves because its tablets may not dissolve correctly.

The alert affects bottles of 10mg, 20mg, 40mg and 80mg tablets that were sold nationwide in 90-, 500- and 1,000-count bottles available by prescription.

In the recall notice, the FDA said the drugs ‘failed dissolution specifications‘, meaning they did not release their active ingredient at the expected rate during testing. Continue reading →

Nearly 20,000 patients at Memorial Sloan Kettering could lose access to critical care because of a contract battle between the renowned cancer hospital and health insurance behemoth UnitedHealthcare.

The two sides have until the end of June to hash out a new deal over reimbursement rates — but are trading blame while patients, many in need of lifesaving care, anxiously wait to see if they will keep in-network treatment.

Patient Lee Kassler, of Plainview, Long Island, said he was in “disbelief” and “shocked” when he found out that he could lose care on July 1 if the Manhattan hospital and health insurance company don’t reach an agreement by June 30.

“Full of anxiety, full of stress, saddened, angry, worried, just a whole host of emotions that I was faced with when I was diagnosed with cancer,” Kassler, who has had a rare, incurable gastric cancer since 2022, told The Post Friday. Continue reading →

The FDA is forcing Pfizer and Moderna to use expanded warning labels about the risks of heart damage tied to Covid vaccines.

The shots previously included warning labels about the rare risks of myocarditis, inflammation of the heart muscle, and pericarditis, inflammation of the sac-like lining surrounding the heart.

The new labels will expand that warning to certain age groups — specifically males aged 16 to 25 who appear to be at the highest risk of the rare complication. Continue reading →